- Home
- HOLO vs NLSP Comparison
HOLO vs NLSP Comparison
Compare HOLO & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOLO
- NLSP
- Stock Information
- Founded
- HOLO 2018
- NLSP 2015
- Country
- HOLO China
- NLSP Switzerland
- Employees
- HOLO N/A
- NLSP N/A
- Industry
- HOLO Computer Software: Programming Data Processing
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- HOLO Technology
- NLSP Health Care
- Exchange
- HOLO Nasdaq
- NLSP Nasdaq
- Market Cap
- HOLO 95.5M
- NLSP 243.8M
- IPO Year
- HOLO N/A
- NLSP 2021
- Fundamental
- Price
- HOLO $4.47
- NLSP $4.55
- Analyst Decision
- HOLO
- NLSP
- Analyst Count
- HOLO 0
- NLSP 0
- Target Price
- HOLO N/A
- NLSP N/A
- AVG Volume (30 Days)
- HOLO 5.0M
- NLSP 33.1K
- Earning Date
- HOLO 10-29-2024
- NLSP 11-01-2024
- Dividend Yield
- HOLO N/A
- NLSP N/A
- EPS Growth
- HOLO N/A
- NLSP N/A
- EPS
- HOLO N/A
- NLSP N/A
- Revenue
- HOLO $32,242,196.00
- NLSP N/A
- Revenue This Year
- HOLO N/A
- NLSP N/A
- Revenue Next Year
- HOLO N/A
- NLSP N/A
- P/E Ratio
- HOLO N/A
- NLSP N/A
- Revenue Growth
- HOLO 326.95
- NLSP N/A
- 52 Week Low
- HOLO $4.00
- NLSP $4.08
- 52 Week High
- HOLO $1,968.00
- NLSP $29.84
- Technical
- Relative Strength Index (RSI)
- HOLO 41.41
- NLSP 40.59
- Support Level
- HOLO $4.83
- NLSP $4.38
- Resistance Level
- HOLO $6.01
- NLSP $5.64
- Average True Range (ATR)
- HOLO 0.92
- NLSP 0.47
- MACD
- HOLO -0.05
- NLSP 0.06
- Stochastic Oscillator
- HOLO 4.86
- NLSP 29.16
About HOLO MicroCloud Hologram Inc.
MicroCloud Hologram Inc, through its subsidiaries, is mainly engaged in holographic Technology. It includes Holographic solutions and Holographic technology services. The company also provides holographic digital twin technology services for customers and has built a holographic digital twin technology resource library.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.